House Passes Bill to Cap Insulin Prices, Which is Sure to Help Big Pharma with Higher Premiums
Townhall
On Thurs., the House passed a bill capping the cost of insulin to $35 per month for most Americans who use it.
Nearly 30M Americans currently live with diabetes, a condition treated with the drug.
This will ensure that Americans are never denied access to the life-saving medication because of economic inequality. Prices of insulin are massively inflated for consumers and complaints about price-fixing only play into the hands of Big Pharma.
Although this may seem compassionate, it doesn't address the core issue and instead simply shifts the cost to health insurers and employers, inevitably leading to higher premiums. It also risks increasing the price of other drugs because the legislation fails to reform the rebate system.